Drug Details
| General Information of the Drug (ID: DR1130) | ||||
|---|---|---|---|---|
| Name |
PD184352
|
|||
| Synonyms |
212631-79-3; CI-1040; PD184352; PD 184352; PD-184352; 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD184352 (CI-1040); CI 1040; CI1040; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD-18435; UNII-R3K9Y00J04; C.I. 1040; CHEMBL105442; R3K9Y00J04; MFCD02683961; NCGC00189074-01; CI-1040 (PD184352); DSSTox_CID_28871; DSSTox_RID_83140; DSSTox_GSID_48945; C17H14ClF2IN2O2; CAS-212631-79-3; PD 184,352; cc-384; MLS006010176; SCHEMBL570330; PD 184352, Free Base; GTPL5676; QCR-25; DTXSID8048945; CHEBI:91353; SYN1031; HMS3244G05; HMS3244G06; HMS3244H05; HMS3265I07; HMS3265I08; HMS3265J07; HMS3265J08; HMS3654I05; AOB87195; BCP01791; EX-A2202; ZINC1489691; Tox21_113363; ABP000919; BDBM50132260; NSC765695; s1020; 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; AKOS022184333; Tox21_113363_1; CCG-269529; CS-0058; DB12429; NSC-765695; SB19417; 2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-(CYCLOPROPYLMETHOXY)-3,4-DIFLUOROBENZAMIDE; NCGC00189074-03; NCGC00189074-05; AC-25483; AS-19373; HY-50295; SMR004701284; CI-1040,PD184352; PD 184352CI-1040; AB0033705; DB-014962; CI-1040; PD184352; FT-0673543; SW219604-1; X7396; EC-000.2331; PD 184352(CI-1040); PD184352 - CI-1040; A25744; PD184352, >=98% (HPLC); S-7729; CI-1040/CI1040,PD184352; 631C793; US8575391, 341; J-505572; BRD-K05104363-001-01-9; Q27076005; 4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; 2-(2-Chloro4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide; Benzamide, 2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluoro-; CI-1040; ; ; 2-(2-Chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Chronic lymphocytic leukaemia [ICD-11: 2A82] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C17H14ClF2IN2O2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl
|
|||
| InChI |
1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)
|
|||
| InChIKey |
GFMMXOIFOQCCGU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 212631-79-3
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | Mitochondrial transmembrane potential | ||||
| Increase | Percentage of sub-G1 apoptotic cells | |||||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Acute promyelocytic leukemia primary blasts derived from patients | Acute promyelocytic leukemia | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Checkpoint kinase-1 (CHK1) | Molecule Info | [3] | |
| Extracellular signal-regulated kinase 2 (ERK2) | Molecule Info | [3] | ||
| Glycogen synthase kinase-3 beta (GSK-3B) | Molecule Info | [3] | ||
| LCK tyrosine protein kinase (LCK) | Molecule Info | [3] | ||
| MAPK/ERK kinase kinase 1 (MAP3K1) | Molecule Info | [4] | ||
| MAPK/ERK kinase kinase 2 (MAP3K2) | Molecule Info | [4] | ||
| Protein kinase B alpha (AKT1) | Molecule Info | [3] | ||
| Protein kinase C alpha (PRKCA) | Molecule Info | [3] | ||
| Rho-associated protein kinase 1 (ROCK1) | Molecule Info | [3] | ||
| Ribosomal protein S6 kinase beta-1 (S6K1) | Molecule Info | [3] | ||
| Serine/threonine-protein kinase Sgk1 (SGK1) | Molecule Info | [3] | ||
| Stress-activated protein kinase 2a (SAPK2A) | Molecule Info | [3] | ||
| Stress-activated protein kinase 2b (SAPK2B) | Molecule Info | [3] | ||
| Stress-activated protein kinase 3 (SAPK3) | Molecule Info | [3] | ||
| Stress-activated protein kinase JNK1 (JNK1) | Molecule Info | [3] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Ubiquitin mediated proteolysis | |||
| 3 | RIG-I-like receptor signaling pathway | |||
| 4 | Neurotrophin signaling pathway | |||
| 5 | GnRH signaling pathway | |||
| 6 | Hepatitis B | |||
| 7 | HTLV-I infection | |||
| 8 | Gap junction | |||
| 9 | FoxO signaling pathway | |||
| 10 | PI3K-Akt signaling pathway | |||
| 11 | Aldosterone-regulated sodium reabsorption | |||
| 12 | ErbB signaling pathway | |||
| 13 | Ras signaling pathway | |||
| 14 | Rap1 signaling pathway | |||
| 15 | cGMP-PKG signaling pathway | |||
| 16 | cAMP signaling pathway | |||
| 17 | Chemokine signaling pathway | |||
| 18 | HIF-1 signaling pathway | |||
| 19 | Sphingolipid signaling pathway | |||
| 20 | Oocyte meiosis | |||
| 21 | mTOR signaling pathway | |||
| 22 | Adrenergic signaling in cardiomyocytes | |||
| 23 | Vascular smooth muscle contraction | |||
| 24 | Dorso-ventral axis formation | |||
| 25 | TGF-beta signaling pathway | |||
| 26 | Axon guidance | |||
| 27 | VEGF signaling pathway | |||
| 28 | Osteoclast differentiation | |||
| 29 | Focal adhesion | |||
| 30 | Adherens junction | |||
| 31 | Signaling pathways regulating pluripotency of stem cells | |||
| 32 | Platelet activation | |||
| 33 | Toll-like receptor signaling pathway | |||
| 34 | NOD-like receptor signaling pathway | |||
| 35 | Natural killer cell mediated cytotoxicity | |||
| 36 | T cell receptor signaling pathway | |||
| 37 | B cell receptor signaling pathway | |||
| 38 | Fc epsilon RI signaling pathway | |||
| 39 | Fc gamma R-mediated phagocytosis | |||
| 40 | TNF signaling pathway | |||
| 41 | Circadian entrainment | |||
| 42 | Long-term potentiation | |||
| 43 | Retrograde endocannabinoid signaling | |||
| 44 | Glutamatergic synapse | |||
| 45 | Cholinergic synapse | |||
| 46 | Serotonergic synapse | |||
| 47 | Long-term depression | |||
| 48 | Regulation of actin cytoskeleton | |||
| 49 | Insulin signaling pathway | |||
| 50 | Progesterone-mediated oocyte maturation | |||
| 51 | Estrogen signaling pathway | |||
| 52 | Melanogenesis | |||
| 53 | Prolactin signaling pathway | |||
| 54 | Thyroid hormone signaling pathway | |||
| 55 | Oxytocin signaling pathway | |||
| 56 | Type II diabetes mellitus | |||
| 57 | Alzheimer's disease | |||
| 58 | Prion diseases | |||
| 59 | Alcoholism | |||
| 60 | Shigellosis | |||
| 61 | Salmonella infection | |||
| 62 | Pertussis | |||
| 63 | Leishmaniasis | |||
| 64 | Chagas disease (American trypanosomiasis) | |||
| 65 | Toxoplasmosis | |||
| 66 | Tuberculosis | |||
| 67 | Hepatitis C | |||
| 68 | Influenza A | |||
| 69 | Pathways in cancer | |||
| 70 | Viral carcinogenesis | |||
| 71 | Proteoglycans in cancer | |||
| 72 | MicroRNAs in cancer | |||
| 73 | Colorectal cancer | |||
| 74 | Renal cell carcinoma | |||
| 75 | Pancreatic cancer | |||
| 76 | Endometrial cancer | |||
| 77 | Glioma | |||
| 78 | Prostate cancer | |||
| 79 | Thyroid cancer | |||
| 80 | Melanoma | |||
| 81 | Bladder cancer | |||
| 82 | Chronic myeloid leukemia | |||
| 83 | Acute myeloid leukemia | |||
| 84 | Non-small cell lung cancer | |||
| 85 | Central carbon metabolism in cancer | |||
| 86 | Choline metabolism in cancer | |||
| 87 | AMPK signaling pathway | |||
| 88 | Leukocyte transendothelial migration | |||
| 89 | Pathogenic Escherichia coli infection | |||
| 90 | Protein processing in endoplasmic reticulum | |||
| 91 | Wnt signaling pathway | |||
| 92 | Dopaminergic synapse | |||
| 93 | Inflammatory mediator regulation of TRP channels | |||
| 94 | Adipocytokine signaling pathway | |||
| 95 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 96 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 97 | Herpes simplex infection | |||
| 98 | Epstein-Barr virus infection | |||
| 99 | Calcium signaling pathway | |||
| 100 | Phosphatidylinositol signaling system | |||
| 101 | Tight junction | |||
| 102 | GABAergic synapse | |||
| 103 | Insulin secretion | |||
| 104 | Thyroid hormone synthesis | |||
| 105 | Endocrine and other factor-regulated calcium reabsorption | |||
| 106 | Salivary secretion | |||
| 107 | Gastric acid secretion | |||
| 108 | Pancreatic secretion | |||
| 109 | Amphetamine addiction | |||
| 110 | Morphine addiction | |||
| 111 | Vibrio cholerae infection | |||
| 112 | African trypanosomiasis | |||
| 113 | Amoebiasis | |||
| 114 | Amyotrophic lateral sclerosis (ALS) | |||
| 115 | NF-kappa B signaling pathway | |||
| 116 | Primary immunodeficiency | |||
| 117 | Cell cycle | |||
| 118 | p53 signaling pathway | |||
| 119 | Hedgehog signaling pathway | |||
| 120 | Hippo signaling pathway | |||
| 121 | Measles | |||
| 122 | Basal cell carcinoma | |||
| 123 | Apoptosis | |||
| 124 | Jak-STAT signaling pathway | |||
| 125 | Glucagon signaling pathway | |||
| 126 | Regulation of lipolysis in adipocytes | |||
| 127 | Carbohydrate digestion and absorption | |||
| 128 | Small cell lung cancer | |||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| 3 | TCR Signaling Pathway | |||
| 4 | FSH Signaling Pathway | |||
| 5 | IL2 Signaling Pathway | |||
| 6 | TNFalpha Signaling Pathway | |||
| 7 | TSH Signaling Pathway | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | Apoptosis signaling pathway | |||
| 3 | T cell activation | |||
| 4 | Ras Pathway | |||
| 5 | B cell activation | |||
| 6 | EGF receptor signaling pathway | |||
| 7 | FGF signaling pathway | |||
| 8 | Alzheimer disease-amyloid secretase pathway | |||
| 9 | Endothelin signaling pathway | |||
| 10 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 11 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
| 12 | Interferon-gamma signaling pathway | |||
| 13 | Interleukin signaling pathway | |||
| 14 | PDGF signaling pathway | |||
| 15 | Parkinson disease | |||
| 16 | TGF-beta signaling pathway | |||
| 17 | VEGF signaling pathway | |||
| 18 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| 19 | CCKR signaling map ST | |||
| 20 | PI3 kinase pathway | |||
| 21 | p53 pathway by glucose deprivation | |||
| 22 | Cytoskeletal regulation by Rho GTPase | |||
| 23 | FAS signaling pathway | |||
| 24 | Integrin signalling pathway | |||
| 25 | Oxidative stress response | |||
| 26 | Toll receptor signaling pathway | |||
| 27 | Alpha adrenergic receptor signaling pathway | |||
| 28 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| 29 | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| 30 | Wnt signaling pathway | |||
| 31 | 5HT2 type receptor mediated signaling pathway | |||
| 32 | Histamine H1 receptor mediated signaling pathway | |||
| 33 | Oxytocin receptor mediated signaling pathway | |||
| 34 | Thyrotropin-releasing hormone receptor signaling pathway | |||
| 35 | p53 pathway feedback loops 2 | |||
| 36 | p38 MAPK pathway | |||
| 37 | Alzheimer disease-presenilin pathway | |||
| 38 | Cadherin signaling pathway | |||
| 39 | Hedgehog signaling pathway | |||
| 40 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 41 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 42 | Huntington disease | |||
| 43 | Hypoxia response via HIF activation | |||
| 44 | p53 pathway | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 4 | Insulin Signalling | |||
| 5 | Leucine Stimulation on Insulin Signaling | |||
| 6 | Activation of PKC through G protein coupled receptor | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | BCR signaling pathway | |||
| 3 | p38 MAPK signaling pathway | |||
| 4 | CD40/CD40L signaling | |||
| 5 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 6 | Osteopontin-mediated events | |||
| 7 | TRAIL signaling pathway | |||
| 8 | CDC42 signaling events | |||
| 9 | FAS (CD95) signaling pathway | |||
| 10 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 11 | TNF receptor signaling pathway | |||
| 12 | Ceramide signaling pathway | |||
| 13 | IFN-gamma pathway | |||
| 14 | ErbB1 downstream signaling | |||
| 15 | JNK signaling in the CD4+ TCR pathway | |||
| 16 | Caspase Cascade in Apoptosis | |||
| 17 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||
| 18 | RAC1 signaling pathway | |||
| 19 | Trk receptor signaling mediated by the MAPK pathway | |||
| 20 | Insulin Pathway | |||
| 21 | Glucocorticoid receptor regulatory network | |||
| 22 | mTOR signaling pathway | |||
| 23 | FoxO family signaling | |||
| 24 | Class I PI3K signaling events | |||
| 25 | Endothelins | |||
| 26 | Signaling events mediated by PRL | |||
| 27 | ErbB4 signaling events | |||
| 28 | GMCSF-mediated signaling events | |||
| 29 | S1P3 pathway | |||
| 30 | EPHB forward signaling | |||
| 31 | S1P4 pathway | |||
| 32 | Presenilin action in Notch and Wnt signaling | |||
| 33 | Signaling events regulated by Ret tyrosine kinase | |||
| 34 | Angiopoietin receptor Tie2-mediated signaling | |||
| 35 | S1P1 pathway | |||
| 36 | Regulation of Telomerase | |||
| 37 | Netrin-mediated signaling events | |||
| 38 | Arf6 downstream pathway | |||
| 39 | Class IB PI3K non-lipid kinase events | |||
| 40 | IL2-mediated signaling events | |||
| 41 | EGF receptor (ErbB1) signaling pathway | |||
| 42 | Ras signaling in the CD4+ TCR pathway | |||
| 43 | Integrins in angiogenesis | |||
| 44 | ATF-2 transcription factor network | |||
| 45 | ErbB2/ErbB3 signaling events | |||
| 46 | BMP receptor signaling | |||
| 47 | ALK1 signaling events | |||
| 48 | PDGFR-beta signaling pathway | |||
| 49 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 50 | Syndecan-1-mediated signaling events | |||
| 51 | Retinoic acid receptors-mediated signaling | |||
| 52 | Nongenotropic Androgen signaling | |||
| 53 | CXCR3-mediated signaling events | |||
| 54 | VEGFR1 specific signals | |||
| 55 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 56 | Syndecan-2-mediated signaling events | |||
| 57 | Cellular roles of Anthrax toxin | |||
| 58 | S1P2 pathway | |||
| 59 | Downstream signaling in naï | |||
| 60 | ||||
| 61 | VEGFR3 signaling in lymphatic endothelium | |||
| 62 | Alpha-synuclein signaling | |||
| 63 | FGF signaling pathway | |||
| 64 | Signaling events mediated by focal adhesion kinase | |||
| 65 | IL4-mediated signaling events | |||
| 66 | IGF1 pathway | |||
| 67 | IL2 signaling events mediated by PI3K | |||
| 68 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 69 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 70 | a6b1 and a6b4 Integrin signaling | |||
| 71 | TGF-beta receptor signaling | |||
| 72 | RhoA signaling pathway | |||
| 73 | Noncanonical Wnt signaling pathway | |||
| 74 | Thromboxane A2 receptor signaling | |||
| 75 | PAR4-mediated thrombin signaling events | |||
| 76 | amb2 Integrin signaling | |||
| 77 | EPHA forward signaling | |||
| 78 | Stabilization and expansion of the E-cadherin adherens junction | |||
| 79 | PAR1-mediated thrombin signaling events | |||
| 80 | N-cadherin signaling events | |||
| 81 | Reelin signaling pathway | |||
| 82 | IL1-mediated signaling events | |||
| 83 | Rapid glucocorticoid signaling | |||
| 84 | Regulation of Androgen receptor activity | |||
| 85 | p75(NTR)-mediated signaling | |||
| 86 | Nephrin/Neph1 signaling in the kidney podocyte | |||
| 87 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 88 | EPO signaling pathway | |||
| 89 | Ephrin B reverse signaling | |||
| 90 | p53 pathway | |||
| 91 | Glypican 3 network | |||
| 92 | IL12 signaling mediated by STAT4 | |||
| 93 | TCR signaling in naï | |||
| 94 | ||||
| 95 | Canonical NF-kappaB pathway | |||
| 96 | TCR signaling in naï | |||
| 97 | Syndecan-4-mediated signaling events | |||
| 98 | IL8- and CXCR2-mediated signaling events | |||
| 99 | IL8- and CXCR1-mediated signaling events | |||
| 100 | Regulation of Ras family activation | |||
| 101 | p73 transcription factor network | |||
| 102 | Plasma membrane estrogen receptor signaling | |||
| 103 | Regulation of p38-alpha and p38-beta | |||
| 104 | IL6-mediated signaling events | |||
| 105 | p38 signaling mediated by MAPKAP kinases | |||
| 106 | Signaling mediated by p38-alpha and p38-beta | |||
| 107 | Regulation of retinoblastoma protein | |||
| 108 | Atypical NF-kappaB pathway | |||
| 109 | IL12-mediated signaling events | |||
| 110 | Glypican 1 network | |||
| 111 | Signaling events mediated by PTP1B | |||
| 112 | SHP2 signaling | |||
| 113 | CXCR4-mediated signaling events | |||
| 114 | IL2 signaling events mediated by STAT5 | |||
| 115 | Fanconi anemia pathway | |||
| 116 | ATR signaling pathway | |||
| 117 | Circadian rhythm pathway | |||
| 118 | Signaling mediated by p38-gamma and p38-delta | |||
| 119 | LPA receptor mediated events | |||
| 120 | Degradation of beta catenin | |||
| 121 | Integrin-linked kinase signaling | |||
| 122 | LKB1 signaling events | |||
| 123 | Canonical Wnt signaling pathway | |||
| 124 | C-MYC pathway | |||
| 125 | Hedgehog signaling events mediated by Gli proteins | |||
| 126 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 127 | Aurora A signaling | |||
| 128 | Insulin-mediated glucose transport | |||
| 129 | Class I PI3K signaling events mediated by Akt | |||
| 130 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 131 | Regulation of nuclear SMAD2/3 signaling | |||
| 132 | Coregulation of Androgen receptor activity | |||
| 133 | FOXA2 and FOXA3 transcription factor networks | |||
| 134 | E-cadherin signaling in the nascent adherens junction | |||
| 135 | E-cadherin signaling in keratinocytes | |||
| 136 | Signaling events mediated by the Hedgehog family | |||
| 137 | HIF-1-alpha transcription factor network | |||
| Reactome | MyD88:Mal cascade initiated on plasma membrane | Click to Show/Hide | ||
| 2 | FCERI mediated MAPK activation | |||
| 3 | TRAF6 mediated NF-kB activation | |||
| 4 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | |||
| 5 | MyD88 cascade initiated on plasma membrane | |||
| 6 | Stimuli-sensing channels | |||
| 7 | RAF-independent MAPK1/3 activation | |||
| 8 | MAPK1 (ERK2) activation | |||
| 9 | Golgi Cisternae Pericentriolar Stack Reorganization | |||
| 10 | ERK/MAPK targets | |||
| 11 | Regulation of actin dynamics for phagocytic cup formation | |||
| 12 | Oxidative Stress Induced Senescence | |||
| 13 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 14 | Oncogene Induced Senescence | |||
| 15 | Regulation of HSF1-mediated heat shock response | |||
| 16 | NCAM signaling for neurite out-growth | |||
| 17 | Recycling pathway of L1 | |||
| 18 | CREB phosphorylation through the activation of Ras | |||
| 19 | Activation of the AP-1 family of transcription factors | |||
| 20 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 21 | Negative regulation of FGFR1 signaling | |||
| 22 | Negative regulation of FGFR2 signaling | |||
| 23 | Negative regulation of FGFR3 signaling | |||
| 24 | Negative regulation of FGFR4 signaling | |||
| 25 | RHO GTPases Activate WASPs and WAVEs | |||
| 26 | RAF/MAP kinase cascade | |||
| 27 | MAP2K and MAPK activation | |||
| 28 | Negative feedback regulation of MAPK pathway | |||
| 29 | Negative regulation of MAPK pathway | |||
| 30 | Signal attenuation | |||
| 31 | Advanced glycosylation endproduct receptor signaling | |||
| 32 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 33 | Growth hormone receptor signaling | |||
| 34 | mTORC1-mediated signalling | |||
| 35 | Apoptotic cleavage of cellular proteins | |||
| 36 | EPHB-mediated forward signaling | |||
| 37 | EPHA-mediated growth cone collapse | |||
| 38 | G alpha (12/13) signalling events | |||
| 39 | Sema4D induced cell migration and growth-cone collapse | |||
| 40 | VEGFA-VEGFR2 Pathway | |||
| 41 | RHO GTPases Activate ROCKs | |||
| 42 | NRAGE signals death through JNK | |||
| 43 | NRIF signals cell death from the nucleus | |||
| 44 | DSCAM interactions | |||
| 45 | JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | |||
| 46 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| 47 | Calmodulin induced events | |||
| 48 | Disinhibition of SNARE formation | |||
| 49 | Regulation of KIT signaling | |||
| 50 | EGFR Transactivation by Gastrin | |||
| 51 | Inactivation, recovery and regulation of the phototransduction cascade | |||
| 52 | Syndecan interactions | |||
| 53 | Acetylcholine regulates insulin secretion | |||
| 54 | Ca2+ pathway | |||
| 55 | Trafficking of GluR2-containing AMPA receptors | |||
| 56 | G alpha (z) signalling events | |||
| 57 | Depolymerisation of the Nuclear Lamina | |||
| 58 | HuR (ELAVL1) binds and stabilizes mRNA | |||
| 59 | WNT5A-dependent internalization of FZD4 | |||
| 60 | VEGFR2 mediated cell proliferation | |||
| 61 | Response to elevated platelet cytosolic Ca2+ | |||
| 62 | NOD1/2 Signaling Pathway | |||
| 63 | p38MAPK events | |||
| 64 | Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |||
| 65 | CDO in myogenesis | |||
| 66 | activated TAK1 mediates p38 MAPK activation | |||
| 67 | KSRP (KHSRP) binds and destabilizes mRNA | |||
| 68 | ADP signalling through P2Y purinoceptor 1 | |||
| 69 | Platelet sensitization by LDL | |||
| 70 | GPVI-mediated activation cascade | |||
| 71 | PIP3 activates AKT signaling | |||
| 72 | Phosphorylation of CD3 and TCR zeta chains | |||
| 73 | Translocation of ZAP-70 to Immunological synapse | |||
| 74 | Generation of second messenger molecules | |||
| 75 | PECAM1 interactions | |||
| 76 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
| 77 | DAP12 signaling | |||
| 78 | CD28 co-stimulation | |||
| 79 | CD28 dependent PI3K/Akt signaling | |||
| 80 | CD28 dependent Vav1 pathway | |||
| 81 | CTLA4 inhibitory signaling | |||
| 82 | PD-1 signaling | |||
| 83 | Interleukin-2 signaling | |||
| 84 | Activation of ATR in response to replication stress | |||
| 85 | Processing of DNA double-strand break ends | |||
| 86 | Presynaptic phase of homologous DNA pairing and strand exchange | |||
| 87 | G2/M DNA damage checkpoint | |||
| 88 | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||
| 89 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |||
| 90 | Degradation of beta-catenin by the destruction complex | |||
| 91 | AKT phosphorylates targets in the cytosol | |||
| 92 | CRMPs in Sema3A signaling | |||
| 93 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
| 94 | S33 mutants of beta-catenin aren't phosphorylated | |||
| 95 | S37 mutants of beta-catenin aren't phosphorylated | |||
| 96 | S45 mutants of beta-catenin aren't phosphorylated | |||
| 97 | T41 mutants of beta-catenin aren't phosphorylated | |||
| 98 | Degradation of GLI2 by the proteasome | |||
| 99 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 100 | Activation of BAD and translocation to mitochondria | |||
| 101 | Translocation of GLUT4 to the plasma membrane | |||
| 102 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
| 103 | AKT phosphorylates targets in the nucleus | |||
| 104 | Negative regulation of the PI3K/AKT network | |||
| 105 | eNOS activation | |||
| 106 | AKT-mediated inactivation of FOXO1A | |||
| 107 | Integrin alphaIIb beta3 signaling | |||
| 108 | Deactivation of the beta-catenin transactivating complex | |||
| 109 | G beta:gamma signalling through PI3Kgamma | |||
| 110 | VEGFR2 mediated vascular permeability | |||
| 111 | TP53 Regulates Metabolic Genes | |||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | Click to Show/Hide | ||
| 2 | DNA Damage Response (only ATM dependent) | |||
| 3 | Interferon type I signaling pathways | |||
| 4 | Insulin Signaling | |||
| 5 | EGF/EGFR Signaling Pathway | |||
| 6 | MAPK Cascade | |||
| 7 | p38 MAPK Signaling Pathway | |||
| 8 | Apoptosis Modulation by HSP70 | |||
| 9 | MAPK Signaling Pathway | |||
| 10 | FAS pathway and Stress induction of HSP regulation | |||
| 11 | MyD88 cascade initiated on plasma membrane | |||
| 12 | Cardiac Hypertrophic Response | |||
| 13 | MyD88 dependent cascade initiated on endosome | |||
| 14 | MyD88:Mal cascade initiated on plasma membrane | |||
| 15 | Fc epsilon receptor (FCERI) signaling | |||
| 16 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 17 | Polycystic Kidney Disease Pathway | |||
| 18 | Apoptosis | |||
| 19 | PDGF Pathway | |||
| 20 | BDNF signaling pathway | |||
| 21 | TNF alpha Signaling Pathway | |||
| 22 | IL-1 signaling pathway | |||
| 23 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 24 | Iron uptake and transport | |||
| 25 | FSH signaling pathway | |||
| 26 | Toll-like receptor signaling pathway | |||
| 27 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| 28 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| 29 | Vitamin A and Carotenoid Metabolism | |||
| 30 | TCR Signaling Pathway | |||
| 31 | ErbB Signaling Pathway | |||
| 32 | Hypothetical Network for Drug Addiction | |||
| 33 | Senescence and Autophagy in Cancer | |||
| 34 | EPO Receptor Signaling | |||
| 35 | Regulation of Actin Cytoskeleton | |||
| 36 | IL-2 Signaling Pathway | |||
| 37 | IL-4 Signaling Pathway | |||
| 38 | TGF beta Signaling Pathway | |||
| 39 | IL-6 signaling pathway | |||
| 40 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 41 | Kit receptor signaling pathway | |||
| 42 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
| 43 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 44 | IL-3 Signaling Pathway | |||
| 45 | Bladder Cancer | |||
| 46 | MAP kinase activation in TLR cascade | |||
| 47 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| 48 | RAF/MAP kinase cascade | |||
| 49 | Nanoparticle-mediated activation of receptor signaling | |||
| 50 | Genes and (Common) Pathways Underlying Drug Addiction | |||
| 51 | EBV LMP1 signaling | |||
| 52 | Signal Transduction of S1P Receptor | |||
| 53 | Nifedipine Activity | |||
| 54 | Aryl Hydrocarbon Receptor | |||
| 55 | Alpha 6 Beta 4 signaling pathway | |||
| 56 | Spinal Cord Injury | |||
| 57 | Integrated Pancreatic Cancer Pathway | |||
| 58 | Oncostatin M Signaling Pathway | |||
| 59 | Corticotropin-releasing hormone | |||
| 60 | Interleukin-11 Signaling Pathway | |||
| 61 | AGE/RAGE pathway | |||
| 62 | B Cell Receptor Signaling Pathway | |||
| 63 | Prostate Cancer | |||
| 64 | Signaling Pathways in Glioblastoma | |||
| 65 | TSLP Signaling Pathway | |||
| 66 | IL-9 Signaling Pathway | |||
| 67 | Endothelin Pathways | |||
| 68 | IL17 signaling pathway | |||
| 69 | Alzheimers Disease | |||
| 70 | IL-7 Signaling Pathway | |||
| 71 | TWEAK Signaling Pathway | |||
| 72 | Leptin signaling pathway | |||
| 73 | RANKL/RANK Signaling Pathway | |||
| 74 | Integrated Breast Cancer Pathway | |||
| 75 | Opioid Signalling | |||
| 76 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 77 | Signaling by FGFR | |||
| 78 | Integrin-mediated Cell Adhesion | |||
| 79 | L1CAM interactions | |||
| 80 | Advanced glycosylation endproduct receptor signaling | |||
| 81 | Heart Development | |||
| 82 | Type II diabetes mellitus | |||
| 83 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 84 | Angiogenesis | |||
| 85 | Physiological and Pathological Hypertrophy of the Heart | |||
| 86 | Regulation of toll-like receptor signaling pathway | |||
| 87 | Osteopontin Signaling | |||
| 88 | IL-5 Signaling Pathway | |||
| 89 | G13 Signaling Pathway | |||
| 90 | Cytoplasmic Ribosomal Proteins | |||
| 91 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
| 92 | TSH signaling pathway | |||
| 93 | Signaling by Insulin receptor | |||
| 94 | TOR Signaling | |||
| 95 | AMPK Signaling | |||
| 96 | Focal Adhesion | |||
| 97 | JAK/STAT | |||
| 98 | Pathogenic Escherichia coli infection | |||
| 99 | Regulation of Microtubule Cytoskeleton | |||
| 100 | Semaphorin interactions | |||
| 101 | GPCR downstream signaling | |||
| 102 | Apoptotic execution phase | |||
| 103 | Androgen receptor signaling pathway | |||
| 104 | Transcriptional activation by NRF2 | |||
| 105 | NLR Proteins | |||
| 106 | Nanoparticle triggered regulated necrosis | |||
| 107 | Signalling by NGF | |||
| 108 | Intrinsic Pathway for Apoptosis | |||
| 109 | DSCAM interactions | |||
| 110 | Apoptosis Modulation and Signaling | |||
| 111 | Osteoclast Signaling | |||
| 112 | Calcium Regulation in the Cardiac Cell | |||
| 113 | Wnt Signaling Pathway | |||
| 114 | Wnt Signaling Pathway and Pluripotency | |||
| 115 | Wnt Signaling Pathway Netpath | |||
| 116 | G Protein Signaling Pathways | |||
| 117 | Myometrial Relaxation and Contraction Pathways | |||
| 118 | Human Complement System | |||
| 119 | Syndecan interactions | |||
| 120 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
| 121 | Signaling by SCF-KIT | |||
| 122 | DAG and IP3 signaling | |||
| 123 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 124 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 125 | miRs in Muscle Cell Differentiation | |||
| 126 | Response to elevated platelet cytosolic Ca2+ | |||
| 127 | Integration of energy metabolism | |||
| 128 | Parkinsons Disease Pathway | |||
| 129 | NGF signalling via TRKA from the plasma membrane | |||
| 130 | Myogenesis | |||
| 131 | Monoamine Transport | |||
| 132 | Oxidative Stress | |||
| 133 | Amyotrophic lateral sclerosis (ALS) | |||
| 134 | Cardiac Progenitor Differentiation | |||
| 135 | miR-targeted genes in muscle cell - TarBase | |||
| 136 | miR-targeted genes in lymphocytes - TarBase | |||
| 137 | miR-targeted genes in leukocytes - TarBase | |||
| 138 | miR-targeted genes in epithelium - TarBase | |||
| 139 | Signal amplification | |||
| 140 | Platelet homeostasis | |||
| 141 | Notch Signaling Pathway | |||
| 142 | Inflammatory Response Pathway | |||
| 143 | DAP12 interactions | |||
| 144 | Host Interactions of HIV factors | |||
| 145 | PIP3 activates AKT signaling | |||
| 146 | TCR signaling | |||
| 147 | Costimulation by the CD28 family | |||
| 148 | DNA Damage Response | |||
| 149 | ATM Signaling Pathway | |||
| 150 | Retinoblastoma (RB) in Cancer | |||
| 151 | Integrated Cancer pathway | |||
| 152 | Cell Cycle | |||
| 153 | Cell Cycle Checkpoints | |||
| 154 | miRNA Regulation of DNA Damage Response | |||
| 155 | Glycogen Metabolism | |||
| 156 | Copper homeostasis | |||
| 157 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 158 | Degradation of beta-catenin by the destruction complex | |||
| 159 | Neural Crest Differentiation | |||
| 160 | Endochondral Ossification | |||
| 161 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 162 | Translocation of GLUT4 to the Plasma Membrane | |||
| 163 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 164 | SREBP signalling | |||
| 165 | Metabolism of nitric oxide | |||
| 166 | TFs Regulate miRNAs related to cardiac hypertrophy | |||